Text written in Basque and translated automatically by Elia without any subsequent editing. SEE ORIGINAL

[Efficacy of anti-Alzheimer drugs in question]

Anti-amyloid drugs against Alzheimer’s do not have a clinically significant effect, according to a comprehensive review of the review conducted by the international reference organization Cochrane.

This review analyzed data from 17 clinical trials and more than 20,000 patients and concluded that they have little effect on cognitive impairment and dementia severity and that the improvements obtained do not reach the maximum thresholds established to be clinically significant.

Several anti-amyloid plaque drugs associated with Alzheimer's have been authorized in recent years, such as lecanemab and donanemab, as they were considered effective in treating the early stages of the disease. Now, however, in this review, the effect of the antiamyloids currently being marketed has been studied, and the results show that although these drugs manage to reduce beta-amyloid plaques in the brain, this reduction does not imply any significant functional or cognitive improvement. And they have also seen that there may be an increased risk of brain inflammation and microhemorrhages.